Background: Amidst the COVID-19 pandemic, university instruction was transitioned online, including an undergraduate nursing clinical course. Charged with developing and executing virtual simulations, an online clinical course was conceived. Method: Simulated clinical experiences were crafted using a combination of student preassignments and video-conferencing facilitated by faculty. Each experience included the collective review of a case study and student-developed care plans before viewing and debriefing a series of videos. Students summarized their experience in a weekly written reflection. Results: Student feedback was examined through their reflections and verbal responses. The videos served as catalysts for robust discussion. Feedback was overwhelmingly positive related to an interactive experience, a heightened sense of teamwork, and enhanced comprehension by sharing differing perspectives of common experiences. Conclusion: This educational innovation was successful in creating an engaging environment that facilitated student learning and a sense of togetherness during a global pandemic. The use of technology enabled the continuity of a productive teaching–learning experience. [ J Nurs Educ . 2020;59(9):522–525.]

We suggest that HCQS causes an initial break in the barrier function of the epidermis by inhibiting TGase activity; this is followed by a physiologic response of the epidermis aimed at barrier restoration. This rather nonspecific stimulus to epidermal proliferation is probably sufficient to trigger psoriasis in predisposed individuals or aggravate it in psoriatic patients.

providers recall past issues from nearly 50 years ago when IUDs, like the Dalkon Shield in the 1970s, were linked to these complications. 10 Research on the newer and current generation of IUDs has dispelled these correlations and shown that the IUD is in fact a safe contraceptive choice. 10 Nevertheless, provider bias against the IUD restricts its use. The Contraceptive CHOICE Project, and other studies, found that barriers cited by women who desire and seek out a reliable birth control method include the lack of information and access to appropriate methods, specifically the IUD. 8,11,12 In the US, only 11.8% of women currently use an IUD. 13 Past research has demonstrated that health care providers' lack of knowledge regarding IUD use leads to decreased access to this form of contraception. 7 In a seminal study in California, Harper et al 10 examined the knowledge and practice patterns of 816 practitioners on the use of IUDs and found that the lack of accurate practitioner beliefs led to less access and use of IUDs for patients. The providers' beliefs negatively affected the recommendation and insertion rates of IUDs to otherwise appropriate women for this method. Harper et al 10 reported that although 94% of providers agreed the IUD was safe, 40% of providers did not offer the IUD as a choice during contraceptive

Highlights Disruption in prenatal care is an opportunity to utilize mhealth to support patients. Amazon Alexa’s responses were not credible in answering common pregnancy questions. Virtual assistants rendering evidence-based replies are valuable supplements to care. Virtual assistants, like Alexa, cannot replace consultations with health providers.

The use of long‐acting reversible contraception, namely, intrauterine device (IUDs) and the subdermal implant, has been recommended to address the high rate of the unintended pregnancy in the United States. IUDs are a safe, highly effective contraceptive method, suitable for most women. The underutilization of IUDs arises in part from the lack of translation of best practices in the clinical setting as well as fears and misperceptions about this contraceptive method held by health care providers and women. This article reviews screening and management of Neisseria gonorrhoeae and Chlamydia trachomatis infection and pelvic inflammatory disease (PID) in women who are using or want to use an IUD. An IUD may be inserted without prior screening for N gonorrhoeae or C trachomatis in women who are at low risk for sexually transmitted infections and asymptomatic. An in situ IUD may remain in the uterus during and after treatment for gonococcal infection, chlamydial infection, or PID. The risk of PID with an IUD in situ is less than 1%. Following IUD best practices, including their use in the context of sexually transmitted infections, can increase the availability of this method for suitable candidates and decrease the unintended pregnancy rate.